Treatments for Anxiety: Meditation and Escitalopram (TAME)

• ClinicalTrials.gov Identifier: NCT03522844
• Recruitment Status: Recruiting
• First Posted: May 11, 2018
• Last Update Posted: July 28, 2020
• Sponsor: Georgetown University
• Collaborator: Patient-Centered Outcomes Research Institute
• Information provided by (Responsible Party): Elizabeth Hoge, Georgetown University

Tracking Information

• First Submitted Date: May 1, 2018
• First Posted Date: May 11, 2018
• Last Update Posted Date: July 28, 2020
• Actual Study Start Date: June 18, 2018
• Estimated Primary Completion Date: January 15, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 1, 2018)

Clinical Global Impression of Severity scale [ Time Frame: 8 weeks ]

The CGI is a measure of symptom severity and is rated by a clinician

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: October 18, 2019)

• Clinical Global Impression- Improvement (CGI-I) [ Time Frame: 8 weeks ]
  The CGI-I measures symptom improvement and is rated by a clinician
• Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A) [ Time Frame: 8 weeks ]
  The SIGH-A assesses general anxiety symptoms and is rated by a clinician
• Liebowitz Social Anxiety Scale (LSAS) [ Time Frame: 8 weeks ]
  The LSAS measures social anxiety and is rated by a clinician
• Panic Disorder Severity Scale (PDSS) [ Time Frame: 8 weeks ]
  The PDSS measures panic symptom severity and is rated by a clinician
• Overall Anxiety Severity and Impairment Scale (OASIS) [ Time Frame: 8 weeks ]
  The OASIS is a patient-reported measure is anxiety symptoms
• Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: 8 weeks ]
  The PSQI is a patient-reported measure of sleep
• Penn State Worry Questionnaire (PSWQ) [ Time Frame: 8 weeks ]
  The PSWQ is a patient-reported measure of worry
• Beck Anxiety Inventory (BAI) [ Time Frame: 8 weeks ]
  The BAI is a patient-reported measure is anxiety symptoms
• PROMIS-Satisfaction with Participation in Social Roles (SPSR) [ Time Frame: 8 weeks ]
  The PROMIS-SPSR is a patient-reported measure of contentment with social roles
• PROMIS- Emotional Distress Scales (ED) [ Time Frame: 8 weeks ]
  The PROMIS-ED scales are patient-reported measures of emotional distress, such as anxiety and depression
• PROMIS-Ability to Participate in Social Roles and Activities (APSRA) [ Time Frame: 8 weeks ]
  The PROMIS-APSRA is a patient-reported measure of ability to perform usual social roles and activities

Original Secondary Outcome Measures (submitted: May 1, 2018)

• Overall Anxiety Severity and Impairment Scale (OASIS) [ Time Frame: 8 weeks ]
  The OASIS is a measure is anxiety symptoms
• Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: 8 weeks ]
  The PSQI is a measure of sleep
• Penn State Worry Questionnaire (PSWQ) [ Time Frame: 8 weeks ]
  The PSWQ is a patient-reported measure of worry

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Treatments for Anxiety: Meditation and Escitalopram
• Official Title: Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety
• Brief Summary: We propose the first randomized, controlled study to assess the comparative effectiveness of Mindfulness-Based Stress Reduction (MBSR) with a medication for anxiety disorders. We will use escitalopram, gold-standard SSRI treatment for patients with anxiety disorders, and will examine the comparative effectiveness of the two treatments on anxiety symptoms and other outcomes important to patients.

Detailed Description

Mindfulness meditation treatments have been growing in popularity and becoming widely disseminated, and people with anxiety are interested in mindfulness. A benefit of mindfulness interventions is that they can be provided outside of a mental health setting, which may make them more acceptable to patients. Although mindfulness meditation is gaining popularity, there is no information how this treatment strategy compares with standard treatment, such as with medication. Patients need more information about the comparison of treatments to be able to make informed decisions about their health care. We propose the first randomized, controlled study to assess the comparative effectiveness of Mindfulness-Based Stress Reduction (MBSR) compared to escitalopram, a standard medication for patients with anxiety disorders such as generalized anxiety disorder, social anxiety disorder, panic disorder, and agoraphobia.

Patients will be randomized into two 8-week treatments: (1) MBSR and (2) escitalopram. To enroll the necessary sample, we will utilize three study sites in different geographic locations that each have strong clinical and research infrastructures: Georgetown University Medical Center, Massachusetts General Hospital and New York University Langone Medical Center. Thus, we will take advantage of three productive teams with previous successful collaborations and experience in mind-body treatment studies.

• Study Type: Interventional
• Study Phase: Phase 4

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Participants will be randomized to receive one of two treatments over the course of 8-weeks. One group will participate in an 8-week Mindfulness-Based Stress Reduction Course and the other group will receive a daily medication treatment (escitalopram).

Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment

Condition

• Anxiety Disorders
• Generalized Anxiety Disorder
• Panic Disorder
• Social Anxiety Disorder
• Agoraphobia

Intervention

• Other: Mindfulness-Based Stress Reduction
  Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
• Drug: Escitalopram
  Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.

Study Arms

• Experimental: Mindfulness-Based Stress Reduction (MBSR)
  Intervention: Other: Mindfulness-Based Stress Reduction
• Active Comparator: Escitalopram
  Intervention: Drug: Escitalopram

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: October 18, 2019): 368
• Original Estimated Enrollment (submitted: May 1, 2018): 370
• Estimated Study Completion Date: May 14, 2021
• Estimated Primary Completion Date: January 15, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Men and women between 18 and 75 years old.
2. Have an anxiety disorder, including: social anxiety disorder (SAD), generalized anxiety disorder (GAD), panic disorder, or agoraphobia
3. Must understand study procedure and be willing to participate in all testing visits and treatment as assigned.
4. Participants must be able to give informed consent to the study procedures.

Exclusion Criteria:

1. Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, post-traumatic stress disorder, obsessive compulsive disorder, eating disorders, bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders.
2. A serious medical condition that may result in surgery or hospitalization.
3. A history of head trauma causing loss of consciousness, or ongoing cognitive impairment
4. Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).
5. Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.
6. Pregnancy as assessed by urine test at screen. Avoidance of pregnancy is also necessary for inclusion in the study.
7. Subjects taking barbiturates, SSRIs, anti-depressants, or antipsychotics. Sleep medications (other than anti-depressants) and benzodiazepines will be allowed, if has been taken at stable dose 4 weeks prior to baseline and the patient plans to continue at the same dose through the trial. Trazadone (for sleep) above 100mg will be disallowed.
8. Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as cognitive behavioral therapy).
9. Individuals who have completed a course of MBSR or an equivalent meditation training in the last year, or have an ongoing daily meditation practice
10. Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.
11. Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and/or labs.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Elizabeth A Hoge, MD; 202-687-0635; eah103@georgetown.edu

Contact: Caroline Armstrong, BA; 202-687-7283; caroline.armstrong@georgetown.edu

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT03522844
• Other Study ID Numbers: 2017-1464
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

IPD Sharing Statement

• Plan to Share IPD: No

• Responsible Party: Elizabeth Hoge, Georgetown University
• Study Sponsor: Georgetown University
• Collaborators: Patient-Centered Outcomes Research Institute
• Investigators: Not Provided
• PRS Account: Georgetown University
• Verification Date: July 2020